At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DRMA Dermata Therapeutics Inc
Market Closed 12-20 16:00:00 EST
1.08
+0.03
+2.86%
盘后1.14
+0.06+5.56%
19:58 EST
High1.15
Low1.06
Vol159.04K
Open1.07
D1 Closing1.05
Amplitude8.28%
Mkt Cap2.20M
Tradable Cap1.61M
Total Shares2.04M
T/O175.62K
T/O Rate10.65%
Tradable Shares1.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.